Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

436 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum: Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis.
Rodríguez-Jorge F, Fernández-Velasco JI, Villarrubia N, Gracia-Gil J, Fernández E, Meca-Lallana V, Díaz-Pérez C, Sainz de la Maza S, Pacheco EM, Quiroga A, Ramió-Torrentà L, Martínez-Yélamos S, Bau L, Monreal E, López-Real A, Rodero-Romero A, Borrega L, Díaz S, Eguía P, Espiño M, Chico-García JL, Barrero FJ, Martínez-Ginés ML, García-Domínguez JM, De la Fuente S, Moreno I, Sainz-Amo R, Mañé-Martínez MA, Caminero A, Castellanos-Pinedo F, Gómez López A, Labiano-Fontcuberta A, Ayuso L, Abreu R, Hernández MÁ, Meca-Lallana J, Martín-Aguilar L, Muriel García A, Masjuan J, Costa-Frossard L, Villar LM. Rodríguez-Jorge F, et al. Among authors: villar lm. Front Immunol. 2024 Dec 19;15:1535051. doi: 10.3389/fimmu.2024.1535051. eCollection 2024. Front Immunol. 2024. PMID: 39749346 Free PMC article.
Effect of Natalizumab on sNfL and sGFAP Levels in Multiple Sclerosis Patients.
Sainz-Amo R, Rodero-Romero A, Monreal E, Chico-García JL, Rodríguez-Jorge F, Fernández-Velasco JI, Villarrubia N, Veiga-González JL, de la Maza SS, Masjuan J, Costa-Frossard L, Villar LM. Sainz-Amo R, et al. Among authors: villar lm. Int J Mol Sci. 2024 Dec 7;25(23):13153. doi: 10.3390/ijms252313153. Int J Mol Sci. 2024. PMID: 39684862 Free PMC article.
Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis.
Comabella M, Hegen H, Villar LM, Rejdak K, Sao-Avilés A, Behrens M, Sastre-Garriga J, Mongay N, Berek K, Martínez-Yelamos S, Pérez-Miralles F, Abdelhak A, Bachhuber F, Tumani H, Lycke J, Carbonell-Mirabent P, Valls-Carbó A, Rosenstein I, Alvarez-Lafuente R, Castillo-Triviño T, Otaegui D, Llufriu S, Blanco Y, Sánchez-López AJ, García-Merino A, Fissolo N, Gutiérrez L, Villacieros-Álvarez J, Monreal E, Wiendl H, Montalban X, Lünemann JD. Comabella M, et al. Among authors: villar lm. J Neurol. 2024 Dec 12;272(1):26. doi: 10.1007/s00415-024-12763-w. J Neurol. 2024. PMID: 39666032 Free PMC article.
Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis.
Rodríguez-Jorge F, Fernández-Velasco JI, Villarrubia N, Gracia-Gil J, Fernández E, Meca-Lallana V, Díaz-Pérez C, Sainz de la Maza S, Pacheco EM, Quiroga A, Ramió-Torrentà L, Martínez-Yélamos S, Bau L, Monreal E, López-Real A, Rodero-Romero A, Borrega L, Díaz S, Eguía P, Espiño M, Chico-García JL, Barrero FJ, Martínez-Ginés ML, García-Domínguez JM, De la Fuente S, Moreno I, Sainz-Amo R, Mañé-Martínez MA, Caminero A, Castellanos F, Gómez López A, Labiano-Fontcuberta A, Ayuso L, Abreu R, Hernández MÁ, Meca-Lallana J, Martín-Aguilar L, Muriel García A, Masjuan J, Costa-Frossard L, Villar LM. Rodríguez-Jorge F, et al. Among authors: villar lm. Front Immunol. 2024 Nov 12;15:1480676. doi: 10.3389/fimmu.2024.1480676. eCollection 2024. Front Immunol. 2024. PMID: 39606235 Free PMC article.
436 results